Pharma-X Consultancy Ltd - Accounts to registrar (filleted)

REGISTERED NUMBER: 07609132 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

PHARMA-X CONSULTANCY LTD

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

Chartered Accountants' Report

7

DIRECTOR:

H I Dhanraj

REGISTERED OFFICE:

29 Filsham Road

St Leonards on Sea

East Sussex

TN38 0PA

REGISTERED NUMBER:

07609132 (England and Wales)

ACCOUNTANTS:

Ashdown Hurrey

Chartered Accountants & Business Advisers

20 Havelock Road

Hastings

East Sussex

TN34 1BP

FIXED ASSETS

Tangible assets

4

2,746

780

Investments

5

-

2,746

780

CURRENT ASSETS

Debtors

6

9,347

12,356

Investments

7

60,407

48,496

Cash at bank

2,584

5,853

72,338

66,705

CREDITORS

Amounts falling due within one year

8

64,902

53,031

NET CURRENT ASSETS

7,436

13,674

TOTAL ASSETS LESS CURRENT
LIABILITIES

10,182

14,454

PROVISIONS FOR LIABILITIES

522

148

NET ASSETS

9,660

14,306

CAPITAL AND RESERVES

Called up share capital

100

Retained earnings

9,560

14,206

SHAREHOLDERS' FUNDS

9,660

14,306

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 29 September 2025 and were signed by:

H I Dhanraj - Director

1.	STATUTORY INFORMATION

Pharma-X Consultancy Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

In preparing the financial statements, the director is required to make an assessment of the ability of the company to continue as a going concern. The director has considered all available evidence for the company which covers the 12 month period from the date of signing these financial statements

On the basis of this consideration, the director is confident that the company has adequate resources to continue in operational existence and to meet its liabilities as they fall due for the foreseeable future. In reaching this conclusion he is satisfied that no material uncertainty exists. As a result of the above, the director has concluded that it remains appropriate to adopt a going concern basis of preparation in these financial statements and that no material uncertainty exists in reaching this conclusion.

Turnover

Turnover represents net invoiced sale of services, excluding value added tax, and is recognised upon completion of the services.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

20% on reducing balance

Computer equipment

-

20% on reducing balance

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4.	TANGIBLE FIXED ASSETS

Plant and

Computer

machinery

equipment

Totals

£

COST

At 1 January 2024

-

2,665

Additions

1,248

1,404

2,652

At 31 December 2024

1,248

4,069

5,317

DEPRECIATION

At 1 January 2024

-

1,885

Charge for year

250

436

686

At 31 December 2024

250

2,321

2,571

NET BOOK VALUE

At 31 December 2024

998

1,748

2,746

At 31 December 2023

-

780

5.	FIXED ASSET INVESTMENTS

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Pharma-X Consultancy Inc 8019 Guyana

Registered office: 34 Garnett Street, Newtown Kitty, Georgetown, Guyana

Nature of business: Trading in pharmaceutical supplies

%

Class of shares:

holding

Ordinary

100.00

31.12.24

31.12.23

£

Aggregate capital and reserves

27,749

13,348

Profit for the year

2,785

1,207

Interface Pharma Inc 42826 Barbados

Registered office: The Grove, 21 Pine Road, Belleville, St Michael, Barbados

Nature of business: Trading in pharmaceutical supplies

%

Class of shares:

holding

Common

100.00

31.12.24

31.12.23

£

Aggregate capital and reserves

94,953

81,953

Profit for the year

1,190

14,994

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

Trade debtors

-

4,356

Interface Pharma Inc

8,000

Tax

1,347

-

9,347

12,356

7.	CURRENT ASSET INVESTMENTS

31.12.24

31.12.23

£

Shares in Pharma-X Consultancy

Inc

11,991

80

Shares in Interface Pharma Inc

48,416

60,407

48,496

8.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

Trade creditors

1,080

-

Tax

1,727

1,711

Other creditors

60,327

48,416

Directors' current accounts

628

2,182

Accrued expenses

1,140

722

64,902

53,031

9.	RELATED PARTY DISCLOSURES

At the period end, H I Dhanraj, who is director, owed £628 to the company (2023 :£2,182 owed from the company). There are no terms attached to this loan.

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Pharma-X Consultancy Ltd for the year ended 31 December 2024 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at icaew.com/membershandbook.

This report is made solely to the director of Pharma-X Consultancy Ltd in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Pharma-X Consultancy Ltd and state those matters that we have agreed to state to the director of Pharma-X Consultancy Ltd in this report in accordance with icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharma-X Consultancy Ltd and its director for our work or for this report.

It is your duty to ensure that Pharma-X Consultancy Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Pharma-X Consultancy Ltd. You consider that Pharma-X Consultancy Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Pharma-X Consultancy Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Ashdown Hurrey

Chartered Accountants & Business Advisers

20 Havelock Road

Hastings

East Sussex

TN34 1BP

29 September 2025